CYAD
vs
DAX Index

Over the past 5 years, CYAD has underperformed DAX Index, delivering a return of -93% compared to the DAX Index's 49% growth.

Stocks Performance
CYAD vs DAX Index

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
CYAD vs DAX Index

Performance Comparison
CYAD vs DAX Index

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
CYAD
Celyad Oncology SA
-13%
161%
147%
84%
-93%
-98%
-96%
DAX Index
Market Index
0%
4%
10%
19%
49%
104%
364%

Celyad Oncology SA
Glance View

Market Cap
29.5m EUR
Industry
Biotechnology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

CYAD Intrinsic Value
0.015 EUR
Overvaluation 98%
Intrinsic Value
Price

See Also

Back to Top